Mapping Immune Markers in Rare Thymic Tumors

Study focused on immune markers PD-1 and PD-L1 in TETs.

70 patients' tumor samples were analyzed.

PD-1 found mostly in immune cells, PD-L1 in tumor cells.

>80 percent of thymic carcinomas expressed high PD-L1.

High PD-L1 linked to advanced disease stages.

Need for further research on prognostic value of PD-L1.

Standardization of PD-L1 testing methods is recommended.